IPSEN INNOVATION SAS

Their core work

IPSEN INNOVATION SAS is the R&D innovation arm of IPSEN, a global specialty pharmaceutical company with drugs in oncology, rare diseases, and neuroscience. In H2020, they contributed senior industry expertise to pre-competitive consortia tackling two strategic bottlenecks: reforming regulatory and market access pathways for adaptive clinical development, and building interoperable data infrastructures for translational drug safety assessment. Their value in consortia is practical — they bring real pharmaceutical pipeline experience and proprietary pre-clinical datasets to problems that academia and regulators cannot solve alone. As a large pharma actor participating (not leading) in multi-stakeholder public-private projects, they act as an industry anchor that lends credibility and domain depth to the research effort.

What they specialise in

How they've shifted over time

IPSEN's early H2020 engagement (2015–2018 via ADAPT-SMART) was firmly downstream — focused on how medicines traverse regulatory and reimbursement systems, with keywords centered on HTA, adaptive design, and multi-stakeholder collaboration. Their second project (eTRANSAFE, 2017–2023) pulled the focus sharply upstream toward the data infrastructure underpinning pre-clinical safety: SEND data formats, data sharing across companies, computational toxicology, and adverse outcome pathways. The direction is clear — from "how do we get medicines approved faster" to "how do we build the data foundations that make safety assessment more predictive and less animal-dependent."

IPSEN is moving toward data-science-driven pre-clinical safety, making them a relevant partner for consortia building computational or AI-assisted toxicology tools, safety database platforms, or regulatory-grade data standards.

How they like to work

IPSEN consistently joins as a participant, never as a coordinator — the role of a large pharma actor that contributes domain expertise and data assets without taking on administrative leadership of public research programmes. Both their projects were large pre-competitive consortia (eTRANSAFE ran six years and included dozens of industry and academic partners), suggesting they are comfortable operating inside complex, multi-organisation structures. A future collaborator should expect IPSEN to be a substantive technical contributor with access to proprietary data, but not the organisation that drives project management.

Despite only two projects, IPSEN has touched 56 unique consortium partners across 13 countries — a sign that both ADAPT-SMART and eTRANSAFE were large pre-competitive industry-academic consortia rather than small bilateral collaborations. Their network is pan-European and likely includes major pharmaceutical companies, national regulatory agencies, and research universities.

What sets them apart

IPSEN brings something rare to research consortia: the perspective of a mid-sized specialty pharma company that is large enough to have substantial pre-clinical safety datasets and regulatory experience, but not so dominant that it controls the consortium's agenda. Unlike academic partners, they can validate whether a proposed data standard or computational model is actually compatible with industry workflows. For anyone building a drug safety, toxicology, or regulatory science consortium that needs genuine industry grounding, IPSEN's track record in exactly these two domains makes them a credible and targeted partner.

Highlights from their portfolio

• eTRANSAFE
  A six-year Innovative Medicines Initiative project (2017–2023) that tackled the hard problem of cross-company pre-clinical safety data sharing, producing interoperable databases and computational models that reduce animal testing — one of the most ambitious data infrastructure efforts in EU pharmaceutical research.
• ADAPT-SMART
  A rare CSA project that brought regulators, HTA bodies, payers, patients, and industry together to co-design adaptive clinical development pathways — addressing the systemic bottleneck between clinical evidence and market access across EU member states.